New hope for rare cancer: virus-based therapy combined with immunotherapy
NCT ID NCT06898970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for angiosarcoma, a rare and aggressive cancer of the blood vessels. The treatment combines a virus that is injected directly into tumors (vusolimogene oderparepvec) with an immunotherapy drug (pembrolizumab). The goal is to see if this combination is safe and can shrink tumors in 18 adults whose cancer has worsened after prior immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill may keep soft tissue sarcoma in check after chemo
- New combo therapy aims to shrink sarcomas
- New Two-Drug immune attack launched against tough cancers
- New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
- New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
- New hope for rare cancers? drug combo shows promise in early trial